SCHEDULE 13D/A: Nuo Therapeutics Secures $200K Loan, Insider Boosts Stake

Nuo Therapeutics, Inc. has secured a $200,000 loan from insider Scott M. Pittman, who increased his beneficial ownership to 11.6% through new warrants.

Summary

• Nuo Therapeutics, Inc. entered into a Loan and Security Agreement on January 21, 2026, with certain lenders, including Scott M. Pittman.
• Scott M. Pittman loaned $200,000 to the Company at the initial closing on January 23, 2026.
• He committed to an additional $210,000 loan by September 30, 2026, if requested by the Company.
• The initial loan bears 10% annual interest, increasing to 12% if the second funding occurs.
• Interest on the notes is payable in Interest Warrants, not cash, at the December 31, 2028 maturity date.
• Principal repayment in cash begins quarterly on March 31, 2027.
• The loan is secured by a lien on all of the Company's assets, including intellectual property.
• Pittman received various warrants, immediately exercisable for 30,050 shares, with an exercise price of $1.50 per share and an expiration date of January 23, 2030.
• His beneficial ownership increased to 5,610,050 shares, representing 11.6% of the 48,281,625 outstanding common shares as of January 21, 2026.

Sentiment

Score: 6

Explanation: The filing indicates a necessary capital infusion for Nuo Therapeutics, which is positive for continued operations. However, the high interest rate, warrant-based interest payments, and pledging of all assets highlight the company's financial challenges and potential future dilution for shareholders. The insider's increased stake shows confidence but also suggests difficulty in attracting external, less dilutive capital.

Positives

• Nuo Therapeutics secured $200,000 in immediate funding and a commitment for an additional $210,000, providing capital for operations.
• The loan interest is payable in warrants, conserving cash for the Company in the short term.
• A significant insider, Scott M. Pittman, increased his beneficial ownership to 11.6%, demonstrating continued confidence in the Company.
• The loan is secured by all company assets, which could provide lenders with more confidence.

Negatives

• The loan bears a relatively high interest rate of 10%, potentially increasing to 12%, which could be a burden on future earnings.
• Interest is paid in warrants, leading to potential future dilution for existing shareholders.
• Prepayment fees, if triggered, are also payable in warrants, further increasing potential dilution.
• The Company's assets, including intellectual property, are pledged as collateral, limiting financial flexibility.
• The need for insider loans suggests challenges in securing traditional financing.

Risks

• Dilution Risk: The issuance of various warrants (Commitment, Origination, Capital, Prepayment, Interest) means a significant number of new shares could be issued, diluting existing shareholders.
• Financial Burden: The 10-12% annual interest rate on the loan, even if paid in warrants, represents a substantial cost.
• Asset Encumbrance: All of the Company's assets, including intellectual property, are pledged as security for the loan, which could hinder future financing or strategic options.
• Prepayment Penalties: Mandatory prepayment events (equity financing, change in control, default) incur significant prepayment fees (up to 2.75% of principal), payable in warrants, exacerbating dilution.
• Reliance on Insider Funding: The Company's reliance on an insider for significant funding may indicate difficulties in attracting external capital.
• Default Risk: The Loan Agreement includes customary representations, warranties, and covenants, and a default would trigger immediate repayment and a 2.75% prepayment fee in warrants.

Future Outlook

The Company has secured short-term financing and a commitment for additional funds, which suggests an intention to continue operations. The structure of the loan, with interest paid in warrants and principal repayment starting in 2027, indicates a need to conserve cash in the near term and a belief in future equity value. The potential for a second funding by September 30, 2026, suggests ongoing capital needs.

Industry Context

This filing indicates a small, publicly traded company (Nuo Therapeutics, Inc.) is relying on insider financing, which is common for smaller companies, especially those in early stages or facing financial challenges, where traditional institutional funding might be difficult to secure. The high interest rate and warrant-based interest payments suggest a higher risk profile compared to more established companies. The pledging of all assets, including IP, is also a common characteristic of distressed or early-stage companies seeking capital.

Comparison to Industry Standards

• The 10-12% interest rate, while high, is not uncommon for small-cap or distressed companies that cannot access lower-cost debt from traditional banks. For example, venture debt for early-stage biotech or medical device companies can range from 8-15%.
• The use of warrants as interest payment and prepayment fees is a common feature in such high-risk, high-yield debt instruments, often seen in private equity or venture capital deals for companies like AcelRx Pharmaceuticals or MannKind Corporation when they seek non-dilutive (cash-wise) but equity-linked financing.
• Pledging all company assets, including intellectual property, is a standard requirement for lenders providing capital to companies with limited tangible assets or a high-risk profile, similar to terms seen in loans to emerging technology firms or biotechs.
• An insider increasing their stake and providing a loan is a strong signal of confidence, often seen in companies like MicroVision or Sorrento Therapeutics where key individuals step in to support operations.

Related Party Transactions

• Scott M. Pittman, the Reporting Person and an insider, provided a $200,000 loan and committed to an additional $210,000 loan to Nuo Therapeutics, Inc.
• In exchange for the loan, Pittman received various warrants (Commitment, Origination Initial, Capital Initial, Origination Second, Capital Second, Prepayment, and Interest Warrants) to purchase shares of Common Stock.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of various warrants for interest payments, prepayment fees, and as part of the loan origination. The pledging of all company assets, including IP, could also impact shareholder value if the company defaults.
• Creditors: The loan is secured by all of the Company's assets, including intellectual property, providing a strong position for the lenders (including Scott M. Pittman) in case of default.
• Employees: Securing financing helps ensure the company's continued operations, which is positive for job security.
• Customers/Suppliers: Continued operations due to financing can ensure ongoing product/service delivery and payment to suppliers.

Next Steps

• The Company may request the second funding of $210,000 from Scott M. Pittman by September 30, 2026.
• The Company will begin quarterly principal repayments on the Notes starting March 31, 2027.
• Interest Warrants will be issued at the Maturity Date of December 31, 2028, or earlier upon prepayment.
• The Company may pursue an equity financing of at least $5 million, which would trigger mandatory prepayment of the Notes.

Key Dates

Recommendation

While the capital infusion provides a lifeline and the insider's increased stake shows confidence, the terms of the loan (high interest, warrant-based payments, asset collateralization) highlight significant financial challenges and potential future dilution. The company is securing necessary funding, but at a cost that suggests underlying weakness. Investors should hold to monitor the company's ability to execute its business plan, manage its debt obligations, and potentially secure less dilutive financing in the future. The immediate impact is likely neutral to slightly positive due to avoiding a liquidity crisis, but long-term concerns remain.

Keywords

Nuo Therapeutics, Schedule 13D, Scott M. Pittman, Loan Agreement, Secured Promissory Note, Warrants, Beneficial Ownership, Insider Loan, Dilution, Corporate Finance, SEC Filing, Equity Financing, Change of Control